AACR 2024 | Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares insights into a Phase II clinical trial evaluating the checkpoint inhibitor nivolumab in combination with lenalidomide and low-dose dexamethasone for the possible treatment of smoldering multiple myeloma (SMM). Although the trial was closed early, Dr Ghobrial explains that spatial proteomics was used to determine the role of immune cells and the regulation of the immune system in the bone marrow niche and comments on the importance of this work in the era of immunotherapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
